Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN to assist with its corporate communications strategy, a move that could elevate the company's profile among investors as it advances both biopharmaceutical and blockchain-focused initiatives. The partnership is designed to generate greater awareness for Apimeds and its wholly owned subsidiary, MindWave Innovations, which is developing institutional digital asset infrastructure that connects treasury, insurance, tokenized assets and blockchain ecosystems.
At the heart of MindWave's offering is a platform that combines insured custody, transparent reporting and technology-driven portfolio management. The goal is to support risk-aware yield on Bitcoin reserves and enable institutional participation in the digital asset economy. By engaging IBN, Apimeds gains access to an investor-focused distribution network that includes more than 5,000 syndication outlets, newsletters, social media channels, InvestorWire and other outreach tools. This broad reach could help the company attract attention from institutional investors and industry participants interested in the convergence of traditional finance and digital assets.
The engagement comes as Apimeds continues to develop non-opioid, biologic-based therapies for pain management, its core focus as a clinical-stage biopharmaceutical company. The dual-track strategy—advancing both drug development and blockchain infrastructure—sets Apimeds apart from typical biotech firms. Its subsidiary, MindWave Innovations, operates four ecosystems under the MindChain umbrella: InsurTech through BlockAssure, which is developing a Bermuda-framework platform applying Bitcoin reserves as regulatory capital to support life and property and casualty underwriting; ClimateTech through AQUAE and the ALCI index, measuring, verifying and tokenizing ecosystem services into institutional-grade assets; HealthTech through the Apitox development program; and RWA Tech through Nexus Global Partners, bringing institutional real estate on-chain within a compliance-first, insurance-enhanced framework.
For investors, the IBN engagement signals a push to improve visibility and communicate the value of these intertwined businesses. IBN's network and tools are designed to cut through information overload and deliver breaking news and actionable content to a wide audience. The full press release can be viewed at https://ibn.fm/PdvmC. Additional information about Apimeds is available at www.ApimedsUS.com, and the latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS.
The strategic communications effort may help Apimeds stand out in a crowded market, where companies that bridge healthcare and digital assets often face skepticism. By leveraging IBN's distribution capabilities, Apimeds aims to educate investors about its unique value proposition and the potential of its blockchain-based platforms to transform insurance, climate finance, healthcare and real estate. As the company progresses with its clinical programs and technology development, the enhanced visibility could play a role in attracting partners, capital and market recognition.
